Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Comment by longondmxon Mar 05, 2018 9:52pm

151 Views

Post# 27665199

RE:Interview with CEO Cameron Groome - Wallstreetanalyzer

Thanks for sharing. CEO continued optimism with lumisort (transaction targeted in 2018/2019) and kynlitic (transaction targeted in 2018). And 20-30 growth in core business sales and much better margins as bioreactor rolls in with more and more with increased sales.

Bullboard Posts

Unique Battery Metals opportunity in Quebec